Fibroheal Woundcare Private Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Fibroheal Woundcare Private Limited - overview
Established
2017
Location
Bangalore, -, India
Primary Industry
Pharmaceuticals
About
Based in India, Fibroheal specializes in advanced wound care solutions, utilizing innovative silk proteins to promote effective wound healing across various healthcare settings. Fibroheal Woundcare Private Limited, founded in 2017 in Bangalore, India, focuses on developing advanced wound care products. The company has closed a total of 5 deals and recently raised INR 63 million in pre-Series A funding on December 15, 2024, to enhance its market strategy and extend its product pipeline. Founders Bharat Tandon and Vivek Mishra lead the company, with Vivek also serving as CEO.
Fibroheal Woundcare Pvt. Ltd. specializes in advanced wound care solutions utilizing silk proteins as a biomaterial for effective wound healing. Their product range includes offerings designed to address various aspects of wound management, such as infection control, moisture balance, scar management, and post-operative care.
Key products include the D-Fibroheal line, which encompasses suture dressings and specialized foams that cater to different types of wounds. These products target healthcare providers, hospitals, and clinics, primarily in markets such as India, Southeast Asia, and Europe. Through their innovative applications of silk proteins, Fibroheal addresses both acute and chronic wound care scenarios, providing effective solutions for healthcare professionals and patients alike. In the most recent fiscal year 2023, Fibroheal Woundcare Pvt.
Ltd. reported a revenue of INR 278,637. 9, with an EBITDA of INR -138,725. 8.
The company generates revenue through direct sales of its advanced wound care products, including flagship items like the D-Fibroheal suture dress and D-Fibroheal Ag foam. They engage in B2B transactions, primarily partnering with healthcare institutions and distributors to reach end-users. Pricing for their products ranges from approximately INR 90 for basic items to INR 2,640 for specialized solutions, allowing clients to efficiently manage their wound care inventories. Fibroheal Woundcare Private Limited aims to leverage the recent funding of INR 63 million to scale up its market strategy, hire additional employees, and enhance its product pipeline in the medical devices segment.
The company plans to introduce new products designed for wound care and expand its market reach into Southeast Asia and Europe by the end of 2025.
Current Investors
Karnataka Asset Management Company, Biotechnology Industry Research Assistance Council, Centre For Cellular And Molecular Platforms
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceuticals, Biomaterials
Website
www.fibroheal.com
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.